KI-7

• CAT Number: I014777
• CAS Number: 1489263-00-4
• Molecular Formula: C23H18N2O2
• Molecular Weight: 354.40
• Purity: ≥95%
• Synonyms: 2-(1-benzylindol-3-yl)-2-oxo-N-phenylacetamide
• InChI: InChI=1S/C23H18N2O2/c26-22(23(27)24-18-11-5-2-6-12-18)20-16-25(15-17-9-3-1-4-10-17)21-14-8-7-13-19(20)21/h1-14,16H,15H2,(H,24,27)
• InChIKey: MQMGZFRIEZRHHJ-UHFFFAOYSA-N
• SMILES: C1=CC=C(C=C1)CN2C=C(C3=CC=CC=C32)C(=O)C(=O)NC4=CC=CC=C4

KI-7 is an A2B adenosine receptor positive allosteric modulator. KI-7 potentiates the cAMP accumulation induced by the non-selective A2B adenosine receptor agonist NECA (EC50=445.8 nM). KI-7 also potentiates the cAMP accumulation induced by the selective A2B adenosine receptor agonist BAY 60-6583 as well as by adenosine with EC50s of 2390 nM and 2550 nM, respectively[1][2].
KI-7 (1 μM; 5-21 days; mesenchymal stem cells) induces a significant increase in mRNA expression of Runx2 and Osterix[1].
KI-7 (1 μM; 15-21 days) induced a significant increase in cell viability in both differentiation stages[1].
KI-7, as A2B adenosine receptor positive allosteric modulator in MSCs, demonstrating it is able to potentiate the effects of either adenosine and synthetic orthosteric A2B adenosine receptor agonists in mediating osteoblast differentiation in vitro. NECA, BAY 60-6583 and KI-7 induce a strong increase in IL-6 production. KI-7 is able to potentiate the effects of orthosteric agonists in both differentiation stages, even if the effect became significant only at 21 days[1].

Reference

[1]. Trincavelli ML, et al. Allosteric modulators of human A2B adenosine receptor. Biochim Biophys Acta. 2014;1840(3):1194-1203.
 [Content Brief]

[2]. Trincavelli ML, et al. Osteoblast differentiation and survival: A role for A2B adenosine receptor allosteric modulators. Biochim Biophys Acta. 2014;1843(12):2957-2966.
 [Content Brief]